Yes I'm thinking this also as a possibility with duration...

Yes I'm thinking this also as a possibility with duration and associated safety of ongoing treatment forming post marketing requirements. Any consideration of DMOAD surrogates forming part of Fast Track approval would surprise me but may now not be in the realm of the impossible. Given the dire situation with opioids any labelling restrictions may not matter once word gets out on pain, function and safety. The indications from PAR-008 and multiple previous studies that it helps slow the progress will not be missed by our distribution partners in any regard.